Itoh K, Ishiwata S, Ishida N, Mizugaki M
Department of Pharmaceutical Sciences, Tohoku University Hospital, Sendai.
Tohoku J Exp Med. 1992 Oct;168(2):329-31. doi: 10.1620/tjem.168.329.
By use of monoclonal antibodies (MoAbs) termed APU-6 and AMA-2, we determined the usefulness of urinary modified nucleosides, pseudouridine and 1-methyladenosine, as markers for malignancy. In patients with leukemia and other forms of cancer, these nucleosides elevated significantly and reflected the disease status of patients. The immunohistochemical analysis showed that cancer cells were specifically stained with the MoAbs. Chemical identification of the cellular components reactive with the MoAbs revealed that APU-6-associated antigens were mainly rRNA and AMA-2-associated antigens were mainly tRNA. These results suggest that APU-6 and AMA-2 would be useful tools for clinical and biological studies of cancer.
通过使用名为APU-6和AMA-2的单克隆抗体（MoAbs），我们确定了尿中修饰核苷——假尿苷和1-甲基腺苷作为恶性肿瘤标志物的效用。在白血病和其他癌症患者中，这些核苷显著升高，并反映了患者的疾病状态。免疫组织化学分析表明，癌细胞被这些单克隆抗体特异性染色。对与单克隆抗体反应的细胞成分进行化学鉴定发现，与APU-6相关的抗原主要是核糖体RNA（rRNA），与AMA-2相关的抗原主要是转运RNA（tRNA）。这些结果表明，APU-6和AMA-2将成为癌症临床和生物学研究的有用工具。
